Page last updated: 2024-11-05

n-hydroxyphthalimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-Hydroxyphthalimide (NHPI) is a versatile organic compound widely employed in oxidation chemistry. Its synthesis typically involves the reaction of phthalic anhydride with hydroxylamine. NHPI acts as a catalyst or co-catalyst in various oxidation reactions, including the selective oxidation of hydrocarbons, alcohols, and amines. Its importance stems from its ability to promote environmentally friendly oxidation processes, often using oxygen as the oxidant. The research interest in NHPI is driven by its potential to replace traditional, environmentally harmful oxidizing agents in chemical synthesis and industrial processes. Its unique properties and versatility make it a valuable tool in organic synthesis, particularly for developing sustainable and efficient oxidation methodologies.'

N-hydroxyphthalimide: causes contact dermititis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10665
CHEMBL ID276057
SCHEMBL ID3182600
SCHEMBL ID1410
MeSH IDM0113318

Synonyms (75)

Synonym
bxi99m81x0 ,
unii-bxi99m81x0
5-21-11-00100 (beilstein handbook reference)
AKOS002387742
BB 0255317
n-hydroxyphalimide
2-hydroxyisoindoline-1,3-dione
ai3-52074
einecs 208-358-1
1h-isoindole-1,3(2h)-dione, 2-hydroxy-
2-hydroxyphthalimide
f 802
brn 0131208
nsc 770
524-38-9
phthalimide, n-hydroxy-
nsc-770
nsc770
1h-isoindole-1, 2-hydroxy-
n-hydroxyphthalimide
wln: t56 bvnvj cq
n-hydroxyphthalimide, 97%
2-hydroxy-isoindole-1,3-dione
bdbm50125808
HMS1667D19
2-hydroxyisoindole-1,3-dione
CHEMBL276057 ,
FT-0650420
inchi=1/c8h5no3/c10-7-5-3-1-2-4-6(5)8(11)9(7)12/h1-4,12h
cfmzsmgampbrbe-uhfffaoysa-
H0395
nhpi
phthaloxime
2-hydroxy-1h-isoindole-1,3(2h)-dione
A829086
BBL009697
2-hydroxyisoindolin-1,3-dione
STL141048
FS-3185
2-hydroxy-2,3-dihydro-1h-isoindole-1,3-dione
AM20060443
AB00534
BP-31016
SCHEMBL3182600
SCHEMBL1410
n-hydroxyphthalimide [mi]
n-hydroxypthalimide
n-hydroxyphtalimide
n-hydoxyphthalimide
n-hydroxyphthalirnide
n-hydroxy-phthalimide
n-hydroxylphthalimide
2-hydroxy-1h-isoindol-1,3(2h)-dione
n-hydroxy-phtalimide
n-hyroxyphthalimide
2-hydroxy-1,3-isoindolinedione
DTXSID7060170
2-hydroxy-1h-isoindole-1,3(2h)-dione #
mfcd00005891
n-(hydroxy)phthalimde
J-509677
CS-W008848
F1565-0110
n-hydroxyphthalimide, purum, >=98.0% (t)
hopht
D77696
n-hydroxyphthalimide, vetec(tm) reagent grade, 97%
2-hydroxyphthalimide;phthalimide,n-hydroxy-
BCP21904
Q26296355
3229-40-1
EN300-86453
J66 ,
2-oxidanylisoindole-1,3-dione
PD127779

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)500.00001.88004.68805.8600AID160322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID50807Anticonvulsant activity by subcutaneous pentylenetetrazole test at a dose of 100 mg/kg against young chicks after 30 min; 0/01991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID160322Inhibitory concentration against cap-dependent endonuclease activity of influenza virus RNP2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors.
AID1827854Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation at 100 uM incubated for 72 hrs by CCK-8 assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Development of Low-Molecular-Weight Compounds Targeting the Cancer-Associated KLF5 Transcription Factor.
AID50802Anticonvulsant activity by maximal electroshock test at a dose of 30 mg/kg against young chicks after 4 hr; 0/11991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID53027Compound was evaluated for effective dose by maximal electroshock test after intraperitoneal administration of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID226707Protective index which is the ratio of TD50 to ED50 of in maximal electroshock test. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID22950Time of peak effect (TPE) for activity1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID392531Antiviral activity against influenza virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID50920Anticonvulsant activity by subcutaneous pentylenetetrazole test at a dose of 30 mg/kg against young chicks after 4 hr; 0/11991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID50943Toxicity test (number of animals exhibiting toxicity / number of animals tested) done at a dose 100 mg/kg against young chicks after 30 min; 8/81991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID50798Anticonvulsant activity by maximal electroshock test at a dose of 100 mg/kg against young chicks after 30 min; 2/31991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID22951Time of peak effect (TPE) for toxicity1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID50918Anticonvulsant activity by subcutaneous pentylenetetrazole test at a dose of 30 mg/kg against young chicks after 30 min; 0/11991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID51075Toxicity test (number of animals exhibiting toxicity / number of animals tested) done at a dose 300 mg/kg against young chicks after 30 min; 4/41991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1827855Cytotoxicity against human CCD841 cells assessed as inhibition of cell proliferation at 100 uM incubated for 72 hrs by CCK-8 assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Development of Low-Molecular-Weight Compounds Targeting the Cancer-Associated KLF5 Transcription Factor.
AID1827853Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation at 100 uM incubated for 72 hrs by CCK-8 assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Development of Low-Molecular-Weight Compounds Targeting the Cancer-Associated KLF5 Transcription Factor.
AID50800Anticonvulsant activity by maximal electroshock test at a dose of 30 mg/kg against young chicks after 30 min; 0/11991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID51067Toxicity test (number of animals exhibiting toxicity / number of animals tested) done at a dose 30 mg/kg against young chicks after 30 min; 0/41991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1363739Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID51069Toxicity test (number of animals exhibiting toxicity / number of animals tested) done at a dose 30 mg/kg against young chicks after 4 hr; 0/21991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID51428Compound was evaluated for toxic dose at peak neurologic deficit after intraperitoneal administration of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID51064Toxicity test (number of animals exhibiting toxicity / number of animals tested) done at a dose 100 mg/kg against young chicks after 4 hr; 4/41991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.00)18.7374
1990's1 (2.00)18.2507
2000's11 (22.00)29.6817
2010's33 (66.00)24.3611
2020's4 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.10 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.74 (4.65)
Search Engine Demand Index68.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.92%)6.00%
Case Studies2 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other49 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]